$XBI $129.81 -4%
Pipeline Updates
$CCXI -43% Adcom briefing docs released. source
$BLRX +52% Positive ph 3 GENESIS results of Motixafortide + G-CSF for multiple myeloma. source
$VXRT +4% First patient enrolled in ph1b Norovirus study. source
$SIGA +1% submits NDA for TIPOXX for smallpox. source
$CYTK -6% Ph 2 cohort 3 of REDWOOD-HCM open for enrollment. source
$CMPI -4% Initiated ph 2 combo study of Vido + Nivo. source
$OBSV +2% Completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® (linzagolix) for patients with moderate to severe endometriosis-associated pain (EAP). Data from the primary endpoint readout are expected in Q4 2021. source
Financial Updates
$COCP +52% $40M bought deal offering w/ HC Wainwright @ $1.54/sh. source
$ESPR -24% Revenue miss. source
$ATNX +20% to acquire Kuur Tx, terms include $70M upfront, and $115M of milestone payments, as cash or ATNX stock. source
$IBIO +27% settled lawsuit with Fraunhofer USA, IBIO receives payments and Fraunhofer USA license to use recombinant protein manufacturing technology. source
$PRQR -8% Yarrow bio in-licensed ASO tech to develop therapy for undisclosed target. source